Cargando…

Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen

Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cellular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as P-glycoprotein/ABCB1 have been shown to confer mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Windt, Tímea, Tóth, Szilárd, Patik, Izabel, Sessler, Judit, Kucsma, Nóra, Szepesi, Áron, Zdrazil, Barbara, Özvegy-Laczka, Csilla, Szakács, Gergely
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510822/
https://www.ncbi.nlm.nih.gov/pubmed/30863990
http://dx.doi.org/10.1007/s00204-019-02417-6
_version_ 1783417475504799744
author Windt, Tímea
Tóth, Szilárd
Patik, Izabel
Sessler, Judit
Kucsma, Nóra
Szepesi, Áron
Zdrazil, Barbara
Özvegy-Laczka, Csilla
Szakács, Gergely
author_facet Windt, Tímea
Tóth, Szilárd
Patik, Izabel
Sessler, Judit
Kucsma, Nóra
Szepesi, Áron
Zdrazil, Barbara
Özvegy-Laczka, Csilla
Szakács, Gergely
author_sort Windt, Tímea
collection PubMed
description Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cellular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as P-glycoprotein/ABCB1 have been shown to confer multidrug resistance in cancer. Although expression of uptake transporters has been confirmed in cancer cells, their role in chemotherapy response has not been systematically investigated. In the present study we have adapted a fluorescence-based cytotoxic assay to characterize the influence of key drug-transporters on the toxicity of approved anticancer drugs. Co-cultures of fluorescently labeled parental and transporter-expressing cells (expressing ABCB1, ABCG2 or OATP2B1) were screened against 101 FDA-approved anticancer drugs, using a novel, automated, triple fluorescence-based cytotoxicity assay. By measuring the survival of parental and transporter-expressing cells in co-cultures, we identify those FDA-approved anticancer drugs, whose toxicity is influenced by ABCB1, ABCG2 or OATP2B1. In addition to confirming known substrates of ABCB1 and ABCG2, the fluorescence-based cytotoxicity assays identified anticancer agents whose toxicity was increased in OATP2B1 expressing cells. Interaction of these compounds with OATP2B1 was verified in dedicated transport assays using cell-impermeant fluorescent substrates. Understanding drug-transporter interactions is needed to increase the efficacy of chemotherapeutic agents. Our results highlight the potential of the fluorescence-based HT screening system for identifying transporter substrates, opening the way for the design of therapeutic approaches based on the inhibition or even the exploitation of transporters in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-019-02417-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6510822
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-65108222019-05-28 Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen Windt, Tímea Tóth, Szilárd Patik, Izabel Sessler, Judit Kucsma, Nóra Szepesi, Áron Zdrazil, Barbara Özvegy-Laczka, Csilla Szakács, Gergely Arch Toxicol In Vitro Systems Membrane transporters play an important role in the absorption, distribution, metabolism and excretion of drugs. The cellular accumulation of many drugs is the result of the net function of efflux and influx transporters. Efflux transporters such as P-glycoprotein/ABCB1 have been shown to confer multidrug resistance in cancer. Although expression of uptake transporters has been confirmed in cancer cells, their role in chemotherapy response has not been systematically investigated. In the present study we have adapted a fluorescence-based cytotoxic assay to characterize the influence of key drug-transporters on the toxicity of approved anticancer drugs. Co-cultures of fluorescently labeled parental and transporter-expressing cells (expressing ABCB1, ABCG2 or OATP2B1) were screened against 101 FDA-approved anticancer drugs, using a novel, automated, triple fluorescence-based cytotoxicity assay. By measuring the survival of parental and transporter-expressing cells in co-cultures, we identify those FDA-approved anticancer drugs, whose toxicity is influenced by ABCB1, ABCG2 or OATP2B1. In addition to confirming known substrates of ABCB1 and ABCG2, the fluorescence-based cytotoxicity assays identified anticancer agents whose toxicity was increased in OATP2B1 expressing cells. Interaction of these compounds with OATP2B1 was verified in dedicated transport assays using cell-impermeant fluorescent substrates. Understanding drug-transporter interactions is needed to increase the efficacy of chemotherapeutic agents. Our results highlight the potential of the fluorescence-based HT screening system for identifying transporter substrates, opening the way for the design of therapeutic approaches based on the inhibition or even the exploitation of transporters in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-019-02417-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-03-12 2019 /pmc/articles/PMC6510822/ /pubmed/30863990 http://dx.doi.org/10.1007/s00204-019-02417-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle In Vitro Systems
Windt, Tímea
Tóth, Szilárd
Patik, Izabel
Sessler, Judit
Kucsma, Nóra
Szepesi, Áron
Zdrazil, Barbara
Özvegy-Laczka, Csilla
Szakács, Gergely
Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
title Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
title_full Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
title_fullStr Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
title_full_unstemmed Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
title_short Identification of anticancer OATP2B1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
title_sort identification of anticancer oatp2b1 substrates by an in vitro triple-fluorescence-based cytotoxicity screen
topic In Vitro Systems
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510822/
https://www.ncbi.nlm.nih.gov/pubmed/30863990
http://dx.doi.org/10.1007/s00204-019-02417-6
work_keys_str_mv AT windttimea identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT tothszilard identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT patikizabel identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT sesslerjudit identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT kucsmanora identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT szepesiaron identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT zdrazilbarbara identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT ozvegylaczkacsilla identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen
AT szakacsgergely identificationofanticanceroatp2b1substratesbyaninvitrotriplefluorescencebasedcytotoxicityscreen